Navigation Links
Pharmaceutical Litigation Partner James Stronski Joins Crowell & Moring
Date:5/4/2011

WASHINGTON, May 4, 2011 /PRNewswire-USNewswire/ -- Crowell & Moring LLP is pleased to announce the addition of partner James K. Stronski to the firm's Intellectual Property Group. Based in the New York office, Stronski is an intellectual property litigator with extensive experience handling cases involving the so-called "Hatch-Waxman" Amendments to the Federal Food Drug & Cosmetic Act, as well as patent, trade secret, trademark, copyrights, and unfair competition matters. Stronski will be joined by counsel Chiemi D. Suzuki. They join the firm from Frommer Lawrence & Haug LLP.

"Jim has significant first-chair patent litigation experience, having successfully handled a variety of bench and jury trials. He is the perfect complement to our New York office and our growing pharmaceutical litigation and life sciences practice. Jim's versatility and experience in handling high-stakes matters is a tremendous asset to our clients," said Mark Supko, chair of the firm's Intellectual Property Group.

Stronski has been litigating cases primarily in federal courts nationwide for over 20 years. He focuses his practice on the representation of generic pharmaceutical companies in patent litigation related to "Hatch-Waxman" matters. These particular cases involve challenges to pharmaceutical patents by companies wanting to introduce generic versions of patented drugs. Stronski has first chaired trials, evidentiary preliminary injunction and Markman hearings, and has argued before the Federal Circuit.  

With considerable experience in both bench and jury trials, preliminary injunction motions and appellate practice, he has represented clients in a wide range of industries including pharmaceuticals, the internet, consumer products, plastics, high-tech composites, and semiconductor manufacturing equipment. He also has first chaired cases, including through trial, before the Trademark Trial and Appeal Board (TTAB), and advises clients on trademark infringement and clearance issues.

"Crowell & Moring is a premier litigation firm that has built a large, first-class Intellectual Property Group, serving the needs of clients internationally. I am looking forward to being part of the firm and expanding its pharmaceutical patent litigation practice. Beyond the strength of Crowell & Moring's practices, I was attracted to the firm because it has been at the forefront in using alternative fee arrangements, or value based billing, that takes a creative 'risk sharing' attitude, utilizing fee arrangements that I believe may  better align the firm's interests with our clients," said Stronski.

Stronski received his B.A. from Dartmouth College and his J.D. from Fordham Law School. After graduation from Fordham, Stronski completed a two-year clerkship for the Honorable Shirley W. Kram of the U.S. District Court for the Southern District of New York.

Suzuki, a New York-based counsel in the firm's Intellectual Property Group, focuses her practice on patent litigation, primarily related to pharmaceutical litigation under the Hatch-Waxman Act. Prior to private practice, Suzuki worked in technology transfer at the Office of Industrial Liaison at Mount Sinai School of Medicine. She received her B.A. from Bryn Mawr College, M.A. in Biotechnology from Columbia University, and her J.D. from University of California, Hastings College of Law.

Crowell & Moring LLP is an international law firm with nearly 500 lawyers representing clients in litigation and arbitration, regulatory, and transactional matters. The firm is internationally recognized for its representation of Fortune 500 companies in high-stakes litigation, as well as its ongoing commitment to pro bono service and diversity. The firm has offices in Washington, DC, New York, Los Angeles, San Francisco, Orange County, Anchorage, London, and Brussels. Visit Crowell & Moring online at www.crowell.com.

Contact:   Jessica O'Neil
(202) 508-8750
joneil@crowell.com


'/>"/>
SOURCE Crowell & Moring LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals plc ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, ... of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ... (Eastern Daylight Time). As previously announced on ... a definitive merger agreement under which Jazz Pharmaceuticals has ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
Breaking Medicine News(10 mins):